Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | APEX1 | P27695 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.37 |
| ▸ | PARG | Q86W56 | 1/20 | 0.35 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.32 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.30 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19692412 | 0.85 | LMNA (0.41) | LMNACYP3A4MAPTAPEX1MAPK1 | |
| SCHEMBL22589110 | 0.78 | PDE3B (0.33) | — | |
| Hydrochloric Acid SCHEMBL7425962 | 0.76 | DYRK1A (0.42) | CYP3A4 | |
| SCHEMBL246588 | 0.70 | AXL (0.35) | CYP3A4MAPTMAPK1MAPK14 | |
| SCHEMBL19706810 | 0.68 | CYP2A6 (0.52) | — | |
| SCHEMBL144590 | 0.67 | MAPT (0.70) | LMNACYP3A4MAPTAPEX1MAPK1 | |
| SCHEMBL29536823 | 0.67 | MAPT (0.70) | LMNACYP3A4MAPTAPEX1MAPK1 | |
| SCHEMBL2340238 | 0.67 | TNF (0.35) | — | |
| SCHEMBL19708686 | 0.67 | LMNA (0.41) | LMNACYP3A4MAPTAPEX1MAPK1 | |
| Hydrochloric Acid SCHEMBL11811816 | 0.66 | MAPT (0.68) | LMNACYP3A4MAPTAPEX1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2585461-B1 | 2,4-DIARYL-SUBSTITUTED [1,8]NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER | MERCK PATENT GMBH (DE) | 2020-02-26 | — | — | EP | disclosed |
| CN-105712991-B | 7 7-azaindole derivatives | 默克专利股份公司 | 2017-12-01 | — | — | CN | disclosed |
| CN-105732617-B | 7 7-azaindole derivatives | 默克专利股份公司 | 2017-12-01 | — | — | CN | disclosed |
| US-9725446-B2 | 7-azaindole derivatives | MERCK PATENT GMBH (DE) | 2017-08-08 | — | — | US | disclosed |
| US-9725446-B2 | 7-azaindole derivatives | MERCK PATENT GMBH (DE) | 2017-08-08 | — | — | US | disclosed |
| CN-105732617-A | 7-azaindole derivatives | 默克专利股份公司 | 2016-07-06 | — | — | CN | disclosed |
| CN-105712991-A | 7-AZAINDOLE DERIVATIVES | 默克专利股份公司 | 2016-06-29 | — | — | CN | disclosed |
| US-20160130269-A1 | 7-AZAINDOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-05-12 | — | — | US | disclosed |
| US-20160130269-A1 | 7-AZAINDOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-05-12 | — | — | US | disclosed |
| CN-103391938-B | Pyrido [2,3-B] pyrazines derivatives and therepic use thereof | MERCK PATENT GMBH (DE) | 2016-02-24 | — | — | CN | disclosed |
| CN-103502247-A | 7-azaindole derivatives | MERCK PATENT GMBH | 2014-01-08 | — | — | CN | disclosed |
| US-20130345227-A1 | PYRIDO [2, 3 - B] PYRAZINE DERIVATIVES AND THEIR THERAPEUTICAL USES | MERCK PATENT GMBH (DE) | 2013-12-26 | — | — | US | disclosed |
| US-20130310391-A1 | 7-AZAINDOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-11-21 | — | — | US | disclosed |
| US-20130310391-A1 | 7-AZAINDOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-11-21 | — | — | US | disclosed |
| CN-103391938-A | Pyrido [2, 3 - b] pyrazine derivatives and their therapeutical uses | MERCK PATENT GMBH | 2013-11-13 | — | — | CN | disclosed |
| EP-2585461-A1 | 2,4- DIARYL - SUBSTITUTED [1,8]NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER | Merck Patent GmbH (DE) | 2013-05-01 | — | — | EP | disclosed |
| US-20130102603-A1 | 2,4-DIARYL - SUBSTITUTED [1,8] NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-04-25 | — | — | US | disclosed |
| US-20130102603-A1 | 2,4-DIARYL - SUBSTITUTED [1,8] NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-04-25 | — | — | US | disclosed |
| WO-2012119690-A1 | PYRIDO [2, 3 - B] PYRAZINE DERIVATIVES AND THEIR THERAPEUTICAL USES | MERCK PATENT GMBH (DE) | 2012-09-13 | — | — | WO | disclosed |
| WO-2012000595-A1 | 2,4- DIARYL - SUBSTITUTED [1,8] NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER | MERCK PATENT GMBH (DE) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310391-A1 | 7-AZAINDOLE DERIVATIVES | PDK1, PDK2, PDK3 | LMNA 3373/4885CYP3A4 2739/4885MAPT 4669/4885 |
| US-20130345227-A1 | PYRIDO [2, 3 - B] PYRAZINE DERIVATIVES AND THEIR THERAPEUTICAL USES | TGFBR1, TGFBR2, PDXK | LMNA 2853/4885CYP3A4 3409/4885MAPT 3626/4885 |
| US-20130102603-A1 | 2,4-DIARYL - SUBSTITUTED [1,8] NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER | TGFBR1, TAB1, TGFBR2 | LMNA 1580/4885CYP3A4 3712/4885MAPT 4149/4885 |
| US-20160130269-A1 | 7-AZAINDOLE DERIVATIVES | PDK1, PDK2, PDK3 | LMNA 3271/4885CYP3A4 2773/4885MAPT 4701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.